Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Mitoxantrone is highly efficient in suppressing multiple sclerosis

According to data supplied by the German Multiple Sclerosis Society's national MS register (DMSG - Deutsche Multiple Sklerose Gesellschaft), up to 10% of German MS patients have been treated with mitoxantrone in the past few years.

1 Sep 2009

Nutra Pharma’s Cobroxin pain reliever is "Best New Product" at the ECRM Conference

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its recently launched pain reliever, Cobroxin, was selected as the “Best New Product” at the Efficient Collaborative Retail Marketing (ECRM) Conference. Cobroxin was chosen as the award recipient by conference attendees, including several of the leading national retailers.

31 Aug 2009

Vision document to guide CHA's support to health reform

The Catholic Health Association of the United States (CHA) has long been committed to a goal of health coverage for all people in the United States. CHA has not, however, endorsed any of the bills currently under consideration.

29 Aug 2009

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Genzyme Corporation (Nasdaq: GENZ) announced today that its supplemental New Drug Application for Clolar® (clofarabine) will be discussed Tuesday, September 1 at a public meeting of the FDA’s Oncologic Drugs Advisory Committee in Silver Spring, Maryland. The panel is expected to consider the clinical trial results Genzyme submitted to support the approval and labeling of Clolar to treat older adult patients with acute myeloid leukemia (AML), the most common type of acute leukemia in adults.

29 Aug 2009

Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic

Facet Biotech Corporation (Nasdaq: FACT) and Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced an agreement for the joint worldwide development and commercialization of TRU-016, a product candidate in phase 1 clinical development for chronic lymphocytic leukemia (CLL).

28 Aug 2009

Bus tour campaign to raise the awareness of patient assistance programs

The 'Help is Here Express' bus tour will be stopping in Virginia throughout the week of August 31 - September 3 at various cities in order to help uninsured and financially-struggling Virginians access information on programs that provide prescription medicines for free or nearly free.

28 Aug 2009

Fast Forward selects IntraLinks to support its funding effort

IntraLinks®, the leading provider of critical information exchange solutions, today announced that Fast Forward™ has selected IntraLinks to help streamline the collection, distribution and tracking of information to support their funding of multiple biotechnology and pharmaceutical companies working on new Multiple Sclerosis (MS) treatments.

28 Aug 2009

Town halls: Even tempers prevail in Wisconsin, but not Phoenix

In Eau Claire, Wisconsin, Rep. Ron Kind, D-Wis, encountered something Democrats may have become unaccustomed to: "a fairly even-tempered crowd" at an "intimate" town hall meeting, Roll Call reports. Kind voted against the reform proposal in the House Ways and Means Committee, but defended current incarnations of the overhaul package during a meeting with local business owners and state National Federation of Independent Business representatives.

28 Aug 2009

American Scientific Resources to acquire the intellectual property of Disintegrator home needle destruction device

American Scientific Resources, Inc. (Pink Sheets: ASFX) (the Company), today confirmed that it has signed a letter of intent to acquire the intellectual property to the Disintegrator home needle destruction device (NDD) (U.S. Patent No. 6,384,362 Patent Application No.: 09/500,504).

27 Aug 2009

XenaCare Holdings to market Cobroxin pain reliever drug in U.S.

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully completed a licensing agreement that grants XenaCare Holdings (OTCBB:XCHO) ongoing exclusive United States marketing and distribution rights for Cobroxin in return for meeting specific minimum performance requirements.

27 Aug 2009

Researchers find the method involved in setting up communications network of connections in the brain

In a new study, researchers at the Montreal Neurological Institute and Hospital (The Neuro), McGill University have found an important mechanism involved in setting up the vast communications network of connections in the brain.

27 Aug 2009

Important development in the treatment of multiple sclerosis

A major step forward, with important implications for understanding how to reduce the severity of multiple sclerosis, has been made by scientists at the University of Bristol. The results are published online today in PNAS.

26 Aug 2009

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

26 Aug 2009

FDA to review Acorda Therapeutics’ NDA for Fampridine-SR

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has confirmed that its Peripheral and Central Nervous System Drugs Advisory Committee will review the Company’s New Drug Application (NDA) for Fampridine-SR on October 14, 2009.

26 Aug 2009

Australian researchers to discover proteins that cause multiple sclerosis

Australian researchers will aim to discover the proteins that cause multiple sclerosis (MS), thanks to a new nationwide research effort. The new research project will receive funding of $1 million over four years, starting this year, under the Australian Research Council's Linkage Projects funding scheme and from MS Research Australia (MSRA), the research arm of MS Australia.

26 Aug 2009

Diplomat Specialty Pharmacy and Ohio Caresource collaborate to develop Chronic Kidney Disease treatment

Diplomat Specialty Pharmacy announced today that its Diplomat Health Services Division is partnering with CareSource in Ohio to slow the progression of Chronic Kidney Disease (CKD), improve clinical outcomes and reduce healthcare costs associated with the disease. As the number of Americans with CKD continues to rise, CareSource is focused on the early identification and treatment of their patients with the illness.

25 Aug 2009

Nutra Pharma submits final packaging and labeling for Cobroxin drug for FDA approval

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully submitted final packaging and labeling to the Food and Drug Administration (FDA) to begin selling Cobroxin, an over-the-counter (OTC) treatment for stage 2 (moderate to severe) chronic pain.

25 Aug 2009

Lpath achieves one of the four Phase 1 objectives by demonstrating its optimized fermentation process

Lpath, Inc., the category leader in lipidomics-based therapeutics, demonstrated commercially acceptable yields in its optimized fermentation process. In doing so, Lpath achieved one of four Phase 1 objectives established by Merck Serono, the exclusive worldwide licensee of ASONEP and Lpath's development partner, and will receive a milestone payment according to the terms of the Merck Serono license agreement.

25 Aug 2009

The California Chronic Care Coalition launches new website to share information on chronic conditions

The California Chronic Care Coalition (CCCC) continues to advance its work toward meaningful and responsible health care reform with the launching of its consumer website: www.chroniccareca.org. Designed to help build a healthier California, the website is aimed at the more than 16 million Californians with chronic conditions such as Asthma, Diabetes, Alzheimer’s Heart disease, Epilepsy and Multiple Sclerosis.

24 Aug 2009

Nutra Pharma launches Cobroxin for chronic pain relief

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has launched an over-the-counter (OTC) pain reliever, Cobroxin, for the treatment of Stage 2 (moderate to severe) chronic pain.

21 Aug 2009

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Mitoxantrone is highly efficient in suppressing multiple sclerosis

Nutra Pharma’s Cobroxin pain reliever is "Best New Product" at the ECRM Conference

Vision document to guide CHA's support to health reform

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic

Bus tour campaign to raise the awareness of patient assistance programs

Fast Forward selects IntraLinks to support its funding effort

Town halls: Even tempers prevail in Wisconsin, but not Phoenix

American Scientific Resources to acquire the intellectual property of Disintegrator home needle destruction device

XenaCare Holdings to market Cobroxin pain reliever drug in U.S.

Researchers find the method involved in setting up communications network of connections in the brain

Important development in the treatment of multiple sclerosis

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

FDA to review Acorda Therapeutics’ NDA for Fampridine-SR

Australian researchers to discover proteins that cause multiple sclerosis

Diplomat Specialty Pharmacy and Ohio Caresource collaborate to develop Chronic Kidney Disease treatment

Nutra Pharma submits final packaging and labeling for Cobroxin drug for FDA approval

Lpath achieves one of the four Phase 1 objectives by demonstrating its optimized fermentation process

The California Chronic Care Coalition launches new website to share information on chronic conditions

Nutra Pharma launches Cobroxin for chronic pain relief

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in